CHICAGO — Patients without disease progression following chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC) should receive osimertinib (Tagrisso) if they harbor EGFR mutations, experts said here.
In the randomized LAURA trial, median progression-free survival (PFS) increased seven-fold when patients received the EGFR inhibitor after definitive chemoradiation, improving from 5.6 months with placebo to an “outstanding” 39.1 months with osimertinib (HR 0.16, 95% CI 0.10-0.24, P
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/asco/110430
